Andrew Pasternak

Andy Pasternak is biopharmaceutical executive and advisor. Most recently, Andy served as Executive Vice President, Chief Strategy Officer at Horizon Therapeutics, a biotechnology company focused on serious, rare autoimmune and inflammatory diseases. At Horizon, which was acquired by Amgen in 2023, Andy was responsible for corporate strategy, business development / M&A, commercial development and portfolio / pipeline management.
Prior to joining Horizon in 2019, Andy was a senior partner at Bain & Company, a leading global consulting firm, where he served as Head of the Healthcare Practice in the Americas. Since the Horizon acquisition, Andy has rejoined Bain as an advisory partner. Earlier in his career, Andy was an analyst in the Investment Banking division of Chemical Securities, Inc. (now part of J.P. Morgan).
Andy is a member of the Board of Directors of Endo, Inc., a specialty pharmaceutical company. Andy also serves on the Board of Directors of Make-A-Wish, Illinois Chapter.
Andy has had a life-long passion for teaching on the topics of business and finance. Andy is an Adjunct Lecturer in the Healthcare Program at the Kellogg School of Management (HCAK), where he teaches a course about the biopharmaceutical industry, and serves on the advisory board of the HCAK program. Andy also teaches a course on personal financial literacy through the Norris Student Center mini-course program at Northwestern University.
Andy received his B.A. in economics from Northwestern University and an MBA from the University of Chicago.
Andy lives in the north suburbs of Chicago with his spouse, Susan, their three children and two dogs.